Last mentioned: Mar 22, 2026
Market Outperformance
Grail shares end the week as a top performer in the healthcare sector, recouping major losses.
TD Cowen Upgrade
TD Cowen upgrades Grail to 'Buy,' arguing the market overreacted to the leadership change.
CEO Transition & Setback
CEO Bob Ragusa retires following reports of a clinical trial setback, causing a sharp drop in GRAL shares.
Grail (GRAL) shares staged a significant recovery this week, outperforming the broader market following a period of heavy selling. The rebound was driven by a high-profile analyst upgrade and a shift in investor sentiment regarding the company's multi-cancer early detection (MCED) platform.
Grail (GRAL) stock staged a major recovery this week, outperforming the broader market after a pivotal upgrade from TD Cowen. The rally marks a significant shift in investor sentiment following a volatile period triggered by a CEO transition and clinical trial concerns.